{"filings":[{"id":805597,"accession_number":"0001213900-26-064144","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2026-06-02T20:00:20+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio reports statistically significant white matter MRI biomarker in Phase 2 Alzheimer's trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["XPro1595 showed significant myelin improvement vs placebo in full mITT (p=0.0028, d=0.46, n=200).","Biomarker-enriched patients (inflammation) showed stronger effect (p=0.0098, d=0.59, n=100).","FDA granted Fast Track designation on May 14, 2026; End-of-Phase 2 alignment secured for Phase 2b/3.","No ARIA-E or ARIA-H observed; favorable safety profile differentiates from amyloid-targeting therapies.","Complete dataset to be presented at AAIC 2026 (July 12-15, London)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442517,"accession_number":"0001213900-26-056599","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2026-05-14T20:05:34+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Fast Track designation to INmune Bio's XPro for early Alzheimer's disease","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Fast Track covers XPro for early Alzheimer's disease (MCI due to AD and mild AD dementia).","XPro is a selective soluble TNF inhibitor targeting neuroinflammation; no approved therapy targets this pathway.","Designation provides more frequent FDA interactions and eligibility for Rolling Review.","Phase 2b/3 registrational trial planned as seamless adaptive design using EMACC and pTau217."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94903,"accession_number":"0001213900-26-052231","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"INmune Bio secures long-term umbilical cord supply for CORDStrom MSC platform via Anthony Nolan agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AN granted exclusive license to use donor materials; INmune Bio added as party with joint liability for royalty payments.","AN receives 2% royalty on net sales of each product, capped at £5M annually; £400+VAT fees per cord tissue, CPI-adjusted annually.","Term runs until 10 years after first commercial sale; either party may terminate with 30 days (IMB/INMB) or 6 months (AN) notice.","Pipeline targets RDEB, CORDStrom-col7a, CORDStrom-TRAIL (oncology), osteoarthritis, and systemic lupus erythematosus (SLE).","Materials handled per GMP and HTA standards; enables global regulatory compliance (FDA, EMA, MHRA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107607,"accession_number":"0001213900-26-021120","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INmune Bio pipeline update: CORDStrom Phase 3 data and XPro1595 FDA alignment for Phase 2b/3 AD trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CORDStrom Phase 3 shows improvements in itch, pain, and skin scores in RDEB; MAA submission expected Q3 2026 for UK.","XPro1595 Phase 2 MINDFuL trial met FDA end-of-Phase 2 meeting; adaptive Phase 2b/3 design with CDR-SB primary accepted.","CORDStrom potential TAM >$1.4B; annual COG $120-180K; anticipated reimbursement ~$700K per year.","XPro1595 showed zero ARIA events in high-risk APOE4+ population; Phase 3 readiness targeted for 2027.","CORDStrom regulatory milestones: RPDD and ODD approved, pre-MAA doc submitted, BLA/MAA submissions planned in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107606,"accession_number":"0001213900-26-019321","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio receives FDA alignment to advance XPro1595 to registrational study in Alzheimer's","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA End-of-Phase 2 meeting yielded alignment to proceed with registrational study in biomarker-enriched early Alzheimer's patients.","Phase 2 MINDFuL trial results and FDA feedback to be detailed in a webinar on Feb 27, 2026 at 9:30 AM ET.","Company will seek a global partnership to maximize XPro1595's clinical and commercial potential.","Key opinion leaders Dr. Michael Woodward and Dr. Sharon Cohen to present MINDFuL trial data and discuss pathway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107605,"accession_number":"0001213900-26-018396","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio to host Feb 26 webinar on new CORDStrom Phase III data for RDEB","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Webinar on February 26, 2026 at 1:00 PM ET to present new MissionEB Phase III data for CORDStrom in RDEB.","Focus: systemic disease-modifying therapy beyond topical care, including EBDASI scores, weight gain, pain/itch reduction, and quality of life.","Featured speakers: Dr. Anna Martinez (Principal Investigator) and CSO Prof. Mark Lowdell.","CORDStrom is a patented allogeneic hucMSC cell medicine positioned for inflammatory/autoimmune diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107604,"accession_number":"0001213900-26-016385","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INmune Bio advances CORDStrom in UK, secures FDA alignment for XPro1595 Alzheimer's program","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted CORDStrom pre-submission package to UK MHRA for RDEB; targets full MAA filing mid-summer 2026.","FDA aligns on integrated Phase 2b/3 design for XPro1595 in early Alzheimer's; CDR-SB sole primary endpoint.","Phase 2b portion to enroll ~300 patients over 9 months; full program ~1,000 participants over 18 months.","Biomarker-driven enrichment strategy (hsCRP, ESR, HbA1c, APOE4) accepted; exploratory non-enriched cohort included.","CORDStrom also benefits from reauthorized Rare Pediatric Disease PRV program through 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107603,"accession_number":"0001213900-26-008204","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INmune Bio updates on CORDStrom RDEB timing and XPro Alzheimer's Phase 2 results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CORDStrom commercial pilot runs completed; MAA to UK MHRA planned mid-2026; BLA to FDA targeted end of 2026.","XPro Phase 2 MINDFuL missed primary endpoint in broad population (n=200) but showed cognitive effect (EMACC d=0.27) in biomarker-defined subpopulation (n=100).","Cash position $27.7M as of Sept 30, 2025, expected to fund operations through year-end 2026.","XPro reduced pTau217 and neuroimaging suggested reduced neurodegeneration in the subgroup.","Regulatory timelines for CORDStrom and XPro remain subject to feedback and manufacturing readiness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123977,"accession_number":"0001213900-25-125282","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"INmune Bio amends 1.35M April 2024 warrants; exercise price cut to $1.95, term extended to June 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exercise price of 1,348,315 outstanding April 2024 warrants reduced to $1.95 per share.","Warrant term extended to expire on June 30, 2026 (from earlier conditional triggers).","Holders paid $0.05 per warrant ($67,416 total) as amendment consideration.","Warrants were originally issued in April 2024 offerings (April 24 & 29, 2024).","Amendment effective upon receipt of signed amendment and full consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123976,"accession_number":"0001213900-25-123880","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"INmune Bio enters $65M ATM equity distribution agreement with A.G.P.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $65M of common stock may be sold from time to time through A.G.P. as sales agent.","Commission of 3.0% of gross proceeds; Company not obligated to sell any shares.","Shares offered via shelf registration effective Aug 7, 2024, with prospectus supplement dated Dec 19, 2025.","A.G.P. will use commercially reasonable efforts consistent with Nasdaq rules and state/federal law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123975,"accession_number":"0001213900-25-120067","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"INmune Bio terminates $75M ATM sales agreement with RBC and BTIG effective Dec 19, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company notified RBC and BTIG of termination on Dec 5 and Dec 9, 2025; effective Dec 19.","No termination penalties or expenses incurred.","Prior to termination, co. raised ~$10.5M net proceeds through sale of 1,353,469 shares.","Original agreement allowed up to $75M in at-the-market offerings since Aug 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123974,"accession_number":"0001213900-25-119217","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"INmune Bio extends poison pill rights agreement to December 31, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment No. 5 to Rights Agreement dated Dec 5, 2025 extends expiration to Dec 31, 2026.","Expiration date will auto-extend for successive one-year terms unless Board decides otherwise.","Rights Agreement originally dated Dec 30, 2020 between INmune Bio and VStock Transfer LLC.","No other changes to terms of the shareholder rights plan were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123973,"accession_number":"0001213900-25-118699","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio: Phase 2 XPro1595 neuroimaging slows neurodegeneration in high-inflammation AD; MSC therapy review published","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New PerpPD+ MRI imaging from Phase 2 MINDFuL trial shows trend toward slowed cortical disarray progression in early AD patients with high neuroinflammation (ADi).","Data presented at CTAD conference; reinforces prior directional improvements on cognitive, biomarker, and neuropsychiatric endpoints.","Additional MRI analyses from MINDFuL trial expected in 2026 to assess gray- and white-matter integrity.","INmune Bio publishes peer-reviewed article on MSC therapies, including CORDStrom platform; BLA/MAA filing for RDEB expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123972,"accession_number":"0001213900-25-117828","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"INmune Bio corrects CEO/CFO base salaries and CEO option grant in employment agreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO David Moss base salary corrected to $454,000 per annum; option grant corrected to 750,000 shares.","CFO Cory Ellspermann base salary corrected to $240,000 per annum.","Amendments effective retroactively to November 26, 2025, to fix clerical errors in original agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123971,"accession_number":"0001213900-25-115921","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"INmune Bio enters new employment agreements with CEO, CFO, and CSO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO David Moss: $500,000 base salary, 50% bonus target, option for 800,000 shares.","CFO Cory Ellspermann: $275,000 base salary, 40% bonus target, option for 300,000 shares.","CSO Mark Lowdell: £300,000 base salary, up to 20% annual bonus, 18-month severance.","Severance for Moss/Ellspermann: 18 months base salary, prorated bonus, and COBRA payments.","New agreements effective November 1, 2025; all include change-of-control equity acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123970,"accession_number":"0001213900-25-112136","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Shareholders approve option repricing to $1.50; CTAD presentations set for Dec 1-4","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting approves repricing of up to 5,511,000 outstanding stock options for employees, execs, and directors to $1.50 per share.","Voting results: 7,144,433 for, 2,926,973 against, 121,836 abstentions.","Repricing effective Nov 18; exercise price set at closing price of $1.50 on Nasdaq that day.","Two presentations at CTAD conference Dec 1-4: Phase 2 MINDFuL trial results for XPro1595 in early Alzheimer’s, and EMACC validation.","Phase 2 trial data on selective soluble TNF neutralizer XPro1595 to be presented as a poster."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123969,"accession_number":"0001213900-25-108315","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INmune Bio: CORDStrom MAA mid-2026, XPro Phase 3 in 2027; $30M cash as of Oct 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CORDStrom Phase 2 in RDEB improves itch/pain; MAA to UK MHRA mid-2026, BLA in US late-2026.","XPro1595 Phase 2 in early AD halts cognitive decline in biomarker-enriched patients; zero ARIA cases.","End-of-Phase-2 FDA meeting for XPro in Q1 2026; Phase 3 start planned for 2027.","Cash $30M as of Oct 14, 2025; market cap ~$50M; ~26.5M shares outstanding.","CORDStrom has Rare Pediatric Disease and Orphan Drug designations; potential PRV."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123968,"accession_number":"0001213900-25-104154","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INmune Bio Q3 net loss $6.5M; appoints new CEO, CFO; INKmune trial meets primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $6.5M from $12.1M YoY; R&D spend cut to $4.9M; cash $27.7M.","David Moss appointed President & CEO replacing Dr. RJ Tesi; Cory Ellspermann named CFO.","XPro1595 Phase 2 MINDFuL results manuscript submitted; End-of-Phase 2 meeting with FDA expected Q1 2026.","INKmune CARE-PC trial met primary endpoint and 2 of 3 secondary endpoints; trial closed to recruitment.","CORDStrom commercial pilot runs complete; MAA submission on track for mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":50000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123967,"accession_number":"0001213900-25-103068","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio to host Q3 2025 results conference call on October 30, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company will report Q3 2025 financial results and provide corporate update on October 30, 2025 at 4:30 PM ET.","Dial-in details: 1-800-225-9448 (US), 1-203-518-9708 (international), Conference ID: INMUNE.","Webcast accessible via provided link; replay available through Nov 13 by dialing 1-844-512-2921 (PIN 11159914).","No financial results disclosed in this press release; results will be provided during the call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123966,"accession_number":"0001213900-25-098702","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio CEO to present at Maxim Growth Summit on RDEB panel","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO David Moss will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit on Oct 22, 2025.","Panel to discuss CORDStrom platform for Recessive Dystrophic Epidermolysis Bullosa (RDEB) treatment.","Summit takes place Oct 22-23 at Hard Rock Hotel, NYC; one-on-one meetings available.","No financial or operational updates provided in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140640,"accession_number":"0001213900-25-093930","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio submits Phase 2 MINDFuL manuscript; highlights subgroup benefit and no ARIA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 MINDFuL trial of XPro1595 missed primary endpoint overall but showed positive trends in ADi subgroup with high inflammatory burden.","No amyloid-related imaging abnormalities (ARIA) observed, even in high-risk patients (APOE4 carriers, anticoagulants, microbleeds).","Manuscript submitted to npj Dementia (Nature Portfolio); preprint available on medRxiv.","Expects FDA feedback for end-of-Phase 2 discussions in Q1 2026.","XPro1595 selectively neutralizes soluble TNF, targeting neuroinflammation in precision medicine approach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140639,"accession_number":"0001213900-25-073089","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"INmune Bio posts $24.5M net loss, CEO replaced; INKmune trial meets endpoints","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $24.5M in Q2 2025 vs $9.7M in Q2 2024; includes $16.5M impairment of in-process R&D intangibles.","CEO RJ Tesi retires; David Moss appointed President & CEO; Cory Ellspermann Interim CFO.","INKmune CaRe PC trial in mCRPC met primary safety and secondary endpoints; trial closed to enrollment.","XPro MINDFuL trial missed primary cognitive endpoints overall; positive trends in enriched biomarker subset.","Cash $33.4M as of June 30; completed $19M registered direct offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140638,"accession_number":"0001213900-25-068745","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio to publish video with additional Phase 2 XPro trial findings after AAIC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Video detailing additional MINDFuL Phase 2 findings of XPro (soluble TNF inhibitor) to be published July 31 at 4 PM ET.","Trial showed consistent cognitive and biomarker benefit after 6 months in amyloid-beta+ patients with ≥2 inflammatory blood biomarkers.","Data presented at AAIC July 29 in Toronto; corporate presentation also filed as Exhibit 99.2.","Dr. Sharon Cohen presented; VP Dr. CJ Barnum cited meaningful changes in short trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140637,"accession_number":"0001213900-25-067791","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio Phase 2 XPro trial misses primary endpoint; positive subpopulation data at AAIC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint not met in mITT group; 208 early-AD participants with inflammation biomarkers.","Consistent benefit seen in subpopulation with Aβ pathology and ≥2 inflammatory biomarkers.","Oral presentation at AAIC on July 29, 2025 at 2:00-3:30 PM ET in Toronto.","Company seeking strategic partnership to accelerate XPro development for Alzheimer's.","Publication of full results anticipated by mid-August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158358,"accession_number":"0001213900-25-059690","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"INmune Bio raises ~$19M in registered direct offering of 3M shares at $6.30/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 3,000,000 common shares at $6.30/share to two healthcare-focused institutional investors.","Gross proceeds of approximately $19 million; net proceeds for working capital and general corporate purposes.","A.G.P./Alliance Global Partners acted as sole placement agent; 7% cash fee paid.","Pricing announced June 27, 2025; closing occurred June 30, 2025.","Shares offered under effective shelf registration statement (Form S-3, File No. 333-279036)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158357,"accession_number":"0001213900-25-059252","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio Phase 2 MINDFuL trial misses primary endpoint; positive subgroup data in inflammation-biomarker AD patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary cognitive endpoint EMACC not met in mITT (n=200); predefined subgroup with ≥2 inflammation biomarkers (n=100) showed cognitive benefit (effect size 0.27).","In same subgroup, behavioral benefit on NPI (effect size -0.24) and biological benefit on pTau217 (effect size -0.20).","XPro well-tolerated; no ARIA-E or ARIA-H; injection site reactions common (80% XPro vs <20% placebo).","Company to file for Breakthrough Therapy designation; End-of-Phase 2 meeting with FDA scheduled for Q4 2025.","Additional MINDFuL analyses to be presented at AAIC in Toronto, July 27-31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158356,"accession_number":"0001213900-25-058380","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio to announce top line Phase 2 MINDFuL Alzheimer's data on June 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Conference call scheduled for June 30, 2025 at 8:00 AM ET to present top line Phase 2 MINDFuL results.","MINDFuL trial is a Phase 2 study in early Alzheimer's disease.","Press release issued June 26, 2025 announcing the upcoming data call.","Dial-in: +1-800-267-6316 (US) or +1-203-518-9783 (international), Conference ID: INMUNE.","Replay available through July 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158355,"accession_number":"0001213900-25-053051","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"INmune Bio shareholders approve share increase to 6.5M; XPro shows amyloid reduction post-TBI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Amended 2021 Stock Incentive Plan, increasing shares from 4M to 6.5M; permits accelerated vesting on change of control.","XPro™ reduced Aβ42, BACE1, and caspase-3 in hippocampus; improved neurological outcomes in transgenic AD mice after TBI.","Collaboration with Virginia Commonwealth Univ. on TBI-AD link; poster presented at Keystone Symposia on June 10, 2025.","All director nominees elected; CBIZ CPAs ratified as auditor for FY2025; non-binding say-on-pay and frequency every three years approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158354,"accession_number":"0001213900-25-043270","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio to present at RBC Capital Markets Global Healthcare Conference on May 20-21","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Fireside chat and 1-on-1 virtual meetings on May 20-21, 2025, at InterContinental Barclay NY.","Presentation at 11:00am EDT; no material financial or pipeline updates announced.","Clinical-stage biotech targeting innate immune system with three product platforms.","No new clinical data, partnerships, or financial disclosures in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158353,"accession_number":"0001213900-25-041082","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INmune Bio Q1 net loss narrows to $9.7M; Alzheimer's Phase 2 data expected late June","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.7M ($0.42 per share) vs $11.0M YoY; R&D expenses down to $7.6M from $8.7M.","Cash $19.3M at March 31; raised $2.1M post-quarter via stock sale; 23.2M shares outstanding.","Top-line results from Phase 2 Alzheimer's trial (MINDFuL) expected in second half of June.","Plans to file BLA for CORDStrom in RDEB in early 2026; partnered with Catapult for manufacturing scale-up.","INKmune Phase I completed, Phase II opened; safety endpoint met; trial expanded to VA Health System."],"consensus_eps_estimate":-0.4794,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":50000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158352,"accession_number":"0001213900-25-040727","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"INmune Bio dismisses Marcum as auditor, engages CBIZ CPAs due to acquisition","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dismissed Marcum LLP on May 7, 2025, following acquisition of its attest business by CBIZ CPAs P.C.","Audit committee approved engagement of CBIZ CPAs as new independent registered public accounting firm for fiscal 2025.","No disagreements or reportable events during 2024, 2023, or through May 7, 2025.","Prior audit report included going concern explanatory paragraph (substantial doubt about ability to continue as going concern)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158351,"accession_number":"0001213900-25-039733","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio schedules Q1 2025 earnings call for May 8; no results released yet","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Press release dated May 5, 2025 announces conference call on May 8, 2025 at 4:30 p.m. ET.","Call will discuss Q1 2025 financial results and provide a corporate update.","Dial-in: 1-800-267-6316 (US) or +1-203-518-9783 (international); Conference ID: INMUNE.","Webcast and replay available; transcript expected within 24 hours."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158350,"accession_number":"0001213900-25-032565","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INmune Bio receives favorable USPTO patentability opinion for CORDStrom platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO, as International Search Authority, issued favorable opinion on all claims of PCT/US25/17028 on April 8, 2025.","Opinion confirms novelty, inventive step, and industrial applicability for CORDStrom pooled hucMSC therapy.","Patent, once granted, would provide IP exclusivity for CORDStrom through at least 2045, subject to extensions.","Company plans to accelerate U.S. national application via Patent Prosecution Highway (PPH) fast-track program.","Follows recent Phase 2 trial data showing CORDStrom reduced pain and itch with early skin integrity signals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158349,"accession_number":"0001213900-25-031590","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio partners with CGT Catapult to scale CORDStrom manufacturing for commercial readiness","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnership with Cell and Gene Therapy Catapult aims to establish large-scale commercial manufacturing for cell therapy platforms.","Initial focus on scaling CORDStrom for RDEB; Phase 2 trial showed reduced pain/itch and improved skin integrity.","INmune estimates 4,000 children with intermediate-to-severe RDEB in US/UK/EU could benefit from CORDStrom.","Following CORDStrom, INmune plans to transition INKmune production to same facility for solid tumor trials.","Manufacturing will leverage CGT Catapult's Stevenage Innovation Centre and existing Royal Free Hospital base."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158348,"accession_number":"0001213900-25-030129","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INmune Bio presents MINDFul Phase 2 baseline data; top-line results expected June 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Poster at AD/PD conference details demographics: mean age 72.5 years, 69.2% APOE ε4 carriers.","64.9% of enrolled patients positive for >1 biomarker of immune dysfunction (hsCRP, ESR, HbA1C, APOE ε4).","Trial enrolled patients with MCI or mild AD; EMACC composite used as primary cognitive endpoint.","Screen failures driven mainly by MMSE inclusion criteria; enrollment completed November 2024.","Top-line results from the 24-week, randomized, placebo-controlled study expected in June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158347,"accession_number":"0001213900-25-027106","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio presents MINDFuL Phase II baseline data at AD/PD 2025; topline results due June 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Poster details baseline demographics of 208 patients (44% MCI, 56% mild AD) enrolled in MINDFuL Phase II trial of XPro1595.","69.2% of patients are APOE ε4 carriers; 64.4% met inclusion criteria for more than one inflammation biomarker.","Primary endpoint is change from baseline in Early and Mild Alzheimer's Cognitive Composite (EMACC) score; topline results expected June 2025.","Patients randomized 2:1 to XPro 1.0 mg/kg or placebo once weekly for 23 weeks; screen failure rate was 72%.","Baseline characteristics show similarity to Phase III trials; no efficacy data disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176736,"accession_number":"0001013762-25-003401","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INmune Bio FY2024 net loss $42.1M; AD02 top-line data expected June 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $42.1M vs $30.0M in FY2023; R&D expenses rose to $33.2M from $20.3M.","Cash and equivalents $20.9M as of Dec 31, 2024; $22.9M shares outstanding.","Completed $27.5M equity offering (incl. ~3.9M warrants) and repaid Silicon Valley Bank loan.","AD02 Phase 2 Alzheimer's trial fully enrolled (208 patients); top-line cognitive results due June 2025.","CORDStrom planning BLA filing in RDEB in 2025/early 2026, eligible for Priority Review Voucher."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176735,"accession_number":"0001013762-25-001309","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio to host Q4 2024 conference call on March 27","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Conference call scheduled for March 27, 2025, at 4:30 p.m. ET to discuss Q4 2024 results and corporate update.","Dial-in: 1-800-225-9448 or 1-203-518-9708; Conference ID: INMUNE.","Webcast available via provided link; transcript and replay available afterward.","No financial results disclosed in this filing; results will be released during the call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176734,"accession_number":"0001213900-25-020064","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INmune Bio files investor presentation on INKmune phase I/II in prostate cancer - no specific data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Preliminary phase I/II results for INKmune in metastatic castration-resistant prostate cancer highlighted in new investor deck.","No specific efficacy or safety data provided in the 8-K excerpt; full slide content not available.","Presentation focuses on in vivo activation of memory-like NK cells (mlNK) using INKmune."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176733,"accession_number":"0001213900-25-012870","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio completes Phase I dose cohort for INKmune in mCRPC, opens Phase II","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Third and highest dose cohort of Phase I completed; no safety issues found.","Scientific Review Committee unanimously voted to open all Phase II cohorts of CaRePC trial.","Low dose cohort showed immunologic effects; higher dose cohorts to assess therapeutic benefits.","CEO R.J. Tesi noted INKmune given in outpatient setting with exemplary safety profile.","CSO Mark Lowdell invited to speak at 10th Annual Innate Killer Summit on March 4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176732,"accession_number":"0001213900-25-011733","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.01","1.02","8.01","9.01"],"status":"ready","headline":"INmune Bio licenses MissionEB data, plans BLA for CORDStrom in pediatric RDEB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plans to submit BLA in 2025 for CORDStrom to treat pediatric RDEB, supported by positive Phase 2 MissionEB data in 30 patients.","Licensed exclusive commercial rights to MissionEB data from Great Ormond Street Hospital for £250k upfront and up to £6M milestone on first marketing authorization.","FDA granted Rare Pediatric Disease Designation (RPDD) Dec 2024 and Orphan Drug Designation (ODD) Jan 2025, preserving PRV eligibility.","CORDStrom well tolerated; severe RDEB patients had >27% sustained itch reduction at 6 months; younger and intermediate patients showed skin and pain improvements.","Terminated existing SVB loan agreement with zero balance and no penalty; no financial impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176731,"accession_number":"0001213900-25-011517","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INmune Bio details CORDStrom regulatory path for RDEB; Phase 2 data shows itch reduction","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CORDStrom Phase 2 in 30 RDEB patients met endpoints on itch and skin scores; well tolerated with no related AEs.","FDA granted Rare Pediatric Disease and Orphan Drug Designations; Type C meeting completed; pre-BLA meeting planned.","Open-label trial starts mid-2025 in UK; INmune to file IND for US inclusion; BLA submission targeted by YE 2025.","Potential US approval/launch in 2026; also seeking MAAs in UK and EU; >$1B peak sales opportunity for ~4,500 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176730,"accession_number":"0001213900-25-007521","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio treats first patient in Phase II portion of INKmune trial for metastatic prostate cancer at VA hospital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient treated in Phase II portion of Phase I/II trial for metastatic castration-resistant prostate cancer (mCRPC) at West LA VA Medical Center.","Patient received the medium dose of INKmune, an NK cell therapy, expanding the ongoing trial to the VA health system.","Approximately 15,000 Veterans diagnosed with prostate cancer annually; 200,000+ Veterans are survivors.","Principal investigator Dr. Matthew Rettig notes the therapy is given as outpatient with minimal side effects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193554,"accession_number":"0001213900-24-106919","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["1.01","3.03","5.02","9.01"],"status":"ready","headline":"INmune Bio extends shareholder rights plan to Dec 2025 and grants stock options to executives and directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights Agreement amended to extend expiration to December 30, 2025.","Non-employee directors each granted options for 32,500 shares at $5.05, vesting Dec 5, 2026.","CEO Raymond Tesi granted options for 226,000 shares at $5.05, vesting Dec 5, 2026.","CFO David Moss granted 223,000 options; CSO Mark Lowdell 140,000 options, same terms.","All grants expire December 4, 2034 and were made under the 2021 Stock Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193553,"accession_number":"0001213900-24-098380","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio completes randomization of 208 patients in Phase 2 Alzheimer's trial; top-line data Q2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total of 208 patients enrolled, exceeding target; 56% mild AD and 44% MCI.","Top-line cognitive results expected in Q2 2025 for the Phase 2 AD02 trial.","Trial uses XPro to target glial-driven neuroinflammation in early Alzheimer's.","Global, blinded, randomized Phase 2 trial; first doses administered to all patients.","CEO RJ Tesi cited overenrollment as a major accomplishment for the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193552,"accession_number":"0001213900-24-097090","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INmune Bio releases new investor presentation; no financial updates in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished a slide deck for use in investor presentations (Exhibit 99.1).","Deck posted on company website under 'Investors – Corporate Presentation' section.","Filing contains no new financial results, clinical data, or guidance changes.","Presentation includes forward-looking statements; no material events disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193551,"accession_number":"0001213900-24-093531","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INmune Bio Q3 net loss $12.1M; Phase 2 Alzheimer's trial fully enrolled; top-line data Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.1M vs $8.6M Q3 2023; R&D expenses $10.1M (up from $6.0M).","Cash and equivalents $33.6M as of Sept 30; raised $13.0M in securities purchase agreement.","Phase 2 AD trial (XPro) fully enrolled with 201 planned patients; top-line data expected Q2 2025.","INKmune in prostate cancer trial showed safety and NK cell activity in first cohort; highest dose cohort dosing began.","Received $2.5M R&D rebate from Australia in July."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":14000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193550,"accession_number":"0001213900-24-091170","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio to host Nov 7 webinar on EMACC cognitive tool for Alzheimer's trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Webinar on Nov 7, 2024 at 1 PM ET, titled \"Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials.\"","Poster on EMACC sensitivity and performance in Phase II Alzheimer's trial presented at CTAD2024.","Company is conducting a Phase II trial of XPro in early AD using EMACC and CDR-SB as endpoints.","No financial results, clinical data readouts, or material business changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193549,"accession_number":"0001213900-24-090766","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio announces Cell Reports publication showing XPro1595 promotes remyelination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Publication in Cell Reports demonstrates XPro1595 converts microglia from demyelinating to remyelinating cell.","Study led by Hellenic Pasteur Institute; identifies solTNF as critical checkpoint for microglia polarization.","Demyelination is core mechanism in neurodegeneration; XPro1595 targets solTNF to restore glia function.","INmune expects top-line Phase II cognitive results in early Alzheimer's patients in first half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193548,"accession_number":"0001213900-24-090366","cik":1711754,"company_name":"Inmune Bio, Inc.","ticker":"INMB","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INmune Bio schedules Q3 2024 earnings call for Oct 31 at 4:30pm EDT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Press release issued Oct 24, 2024 announcing conference call date.","Call on Thursday, October 31, 2024 at 4:30pm ET to discuss Q3 results and corporate update.","Dial-in: 1-800-343-4136 (US), 1-203-518-9843 (intl); Conference ID: INMUNE.","Webcast and replay available; transcript expected within 24 hours of call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":36820582.13214286,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-10-24T23:59:59+00:00|193548"}